Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?

As of 1 August 2025, the valuation grade for Regeneron Pharmaceuticals, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 16, an EV to EBITDA of 13.64, and a Price to Book Value of 2.29.
In comparison to peers, Regeneron has a P/E ratio lower than Eli Lilly & Co. at 40.89 and Johnson & Johnson at 26.18, suggesting it may be more attractively priced relative to these competitors. However, it is slightly higher than Merck & Co., Inc. at 15.68, which is also considered attractive. Notably, Regeneron's stock has underperformed against the S&P 500 over the past year, with a return of -47.43% compared to the index's 17.14%, reinforcing the notion that the stock may be fairly valued in light of its recent performance.